Pearl received FDA clearance extending Second Opinion to panoramic radiographs, covering detection of suspected caries, periapical radiolucencies, and impacted third molars. The clearance was supported by a standalone performance study and a fully crossed multi reader, multi case study, with the company reporting stable performance across gender, geography, and imaging device subgroups. With this clearance the platform spans bitewing, periapical, panoramic, and CBCT imaging.
Our readThe clinically interesting part is the study design, not the clearance itself. A fully crossed multi reader, multi case study is the appropriate design for a reader assistance claim, because it measures whether clinicians perform better with the tool rather than whether the model performs well alone, and relatively few AI vendors in any specialty run one. The reported stability of performance across gender, geography, and imaging device subgroups is also a genuine fairness disclosure, which remains the emptiest axis across this index. Buyers should still confirm that the imaging devices in their own practice are represented in the validation population.